To promote lasting impact, cancer drugs should force dying cells to alert immune response
WASHINGTON — A new finding in basic science should trigger a "change in thinking" about how cancer drugs might be developed and tested for maximum effectiveness, says Louis M. Weiner, M.D., director of the Georgetown Lombardi Comprehensive Cancer Center, in a "Clinical Implications of Basic Research" article titled
Tumor-Cell Death, Autophagy, and Immunity published in the March 22 issue of the New England Journal of Medicine (NEJM).
An internationally known expert in immunotherapy research, Weiner was invited, along with Michael T. Lotze, M.D. from the University of ...



